Advertisement

Relation of Patient Age and Mortality to Reported Contraindications to Early Beta-Blocker Use for Non–ST-Elevation Acute Coronary Syndrome

Published:September 28, 2009DOI:https://doi.org/10.1016/j.amjcard.2009.06.054
      We evaluated the reported contraindications to early β-blocker use and associated mortality within and across patient age groups. Contraindications to early β-blocker use were evaluated in patients with non-ST-elevation acute coronary syndrome in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) initiative from February 2003 to December 2006. The prevalence, reasons, and trends in the contraindications were evaluated by age (≤65, 66 to 74, and ≥75 years). The associations between the reported contraindications and in-hospital mortality were determined within and compared across age groups using the logistic generalized estimating equations method, adjusting for baseline patient characteristics. Of 112,448 patients, 11,711 (10.4%) had a reported contraindication to early β-blocker use. The prevalence varied by age (≤65, 7.9%; 66 to 74, 10.6%; and ≥75, 13.4%; p <0.0001). No significant changes were seen over time, except for a small increase in patients ≤65 years (p = 0.001). Among the hospitals with >40 patients in the registry, the median hospital level rate of reported contraindications was 9.9% (interquartile range 6.7% to 14.3%). The distribution of rates was more widespread among the hospitals' older versus younger patients. In all age groups, a statistically significant greater association was found with in-hospital mortality in those with reported contraindications versus those without contraindications who received a β blocker (adjusted odds ratio 2.81, 95% confidence interval 2.28 to 3.46; adjusted odds ratio 2.50, 95% confidence interval 2.07 to 3.03; adjusted odds ratio 2.11, 95% confidence interval 1.88 to 2.37, for ages ≤65, 66 to 74, and ≥75 years, respectively). The strength of the association was similar across all age groups (interaction p = 0.19). The reported contraindications to early β-blocker use were common and increased with age. The contraindications were independently associated with greater in-hospital mortality, underscoring the importance of accurately identifying contraindications. In conclusion, the results did not indicate any disparity in reporting the contraindications according to patient age.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hoekstra J.W.
        • Pollack Jr, C.V.
        • Roe M.T.
        • Peterson E.D.
        • Brindis R.
        • Harrington R.A.
        • Christenson R.H.
        • Smith S.C.
        • Ohman E.M.
        • Gibler W.B.
        Improving the care of patients with non–ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative.
        Acad Emerg Med. 2002; 9: 1146-1155
        • Liang K.
        • Zeger S.
        Longitudinal data analysis using generalized linear models.
        Biometrika. 1986; 73: 13-22
        • Eagle K.A.
        • Lim M.J.
        • Dabbous O.H.
        • Pieper K.S.
        • Goldberg R.J.
        • Van de Werf F.
        • Goodman S.G.
        • Granger C.B.
        • Steg P.G.
        • Gore J.M.
        • Budaj A.
        • Avezum A.
        • Flather M.D.
        • Fox K.A.
        A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.
        JAMA. 2004; 291: 2727-2733
        • Norwegian Multicenter Study Group
        Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction.
        N Engl J Med. 1981; 304: 801-807
        • Hjalmarson A.
        • Elmfeldt D.
        • Herlitz J.
        • Holmberg S.
        • Málek I.
        • Nyberg G.
        • Rydén L.
        • Swedberg K.
        • Vedin A.
        • Waagstein F.
        • Waldenström A.
        • Waldenström J.
        • Wedel H.
        • Wilhelmsen L.
        • Wilhelmsson C.
        Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial.
        Lancet. 1981; 2: 823-827
        • Beta-blocker Heart Attack Trial Research Group
        A randomized trial of propranolol in patients with acute myocardial infarction.
        JAMA. 1982; 247: 1707-1714
        • MIAMI Trial Research Group
        Metoprolol in acute myocardial infarction (MIAMI): a randomised placebo-controlled international trial.
        Eur Heart J. 1985; 6: 199-211
        • TIMI Study Group
        Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial.
        N Engl J Med. 1989; 320: 618-627
        • Roberts R.
        • Rogers W.J.
        • Mueller H.S.
        • Lambrew C.T.
        • Diver D.J.
        • Smith H.C.
        • Willerson J.T.
        • Knatterud G.L.
        • Forman S.
        • Passamani E.
        Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B study.
        Circulation. 1991; 83: 422-437
        • Gheorghiade M.
        • Goldstein S.
        Beta-blockers in the post-myocardial infarction patient.
        Circulation. 2002; 106: 394-398
        • Gottlieb S.S.
        • McCarter R.J.
        • Vogel R.A.
        Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction.
        N Engl J Med. 1998; 339: 489-497
        • Goldberg R.J.
        • Spencer F.A.
        • Steg P.G.
        • Flather M.
        • Montalescot G.
        • Gurfinkel E.P.
        • Kennelly B.M.
        • Goodman S.G.
        • Dedrick R.
        • Gore J.M.
        Increasing use of single and combination medical therapy in patients hospitalized for acute myocardial infarction in the 21st century: a multinational perspective.
        Arch Intern Med. 2007; 167: 1766-1773
        • Krumholz H.M.
        • Radford M.J.
        • Wang Y.
        • Chen J.
        • Marciniak T.A.
        Early beta-blocker therapy for acute myocardial infarction in elderly patients.
        Ann Intern Med. 1999; 131: 648-654
        • Antman E.M.
        • Anbe D.T.
        • Armstrong P.W.
        • Bates E.R.
        • Green L.A.
        • Hand M.
        • Hochman J.S.
        • Krumholz H.M.
        • Kushner F.G.
        • Lamas G.A.
        • Mullany C.J.
        • Ornato J.P.
        • Pearle D.L.
        • Sloan M.A.
        • Smith Jr, S.C.
        • Alpert S.S.
        • Anderson J.L.
        • Faxon D.P.
        • Fuster V.
        • Gibbons R.J.
        • Gregoratos G.
        • Halperin J.L.
        • Hiratzka L.F.
        • Hunt S.A.
        • Jacobs A.K.
        ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the ACC/AHA Task Force on Practice guidelines.
        J Am Coll Cardiol. 2004; 44: e1-e211
        • Anderson J.L.
        • Adams C.D.
        • Antman E.M.
        • Bridges C.R.
        • Califf R.M.
        • Casey Jr, D.E.
        • Chavey II, W.E.
        • Fesmire F.M.
        • Hochman J.S.
        • Levin T.N.
        • Lincoff A.M.
        • Peterson E.D.
        • Theroux P.
        • Wenger N.K.
        • Wright R.S.
        • Smith Jr, S.C.
        • Jacobs A.K.
        • Adams C.D.
        • Halperin J.L.
        • Hunt S.A.
        • Krumholz H.M.
        • Kushner F.G.
        • Lytle B.W.
        • Nishimura R.
        • Ornato J.P.
        ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the ACC/AHA Task Force on Practice guidelines.
        J Am Coll Cardiol. 2007; 50: e1-e157
        • Krumholz H.M.
        • Anderson J.L.
        • Bachelder B.L.
        • Fesmire F.M.
        • Fihn S.D.
        • Foody J.M.
        • Ho P.M.
        • Kosiborod M.N.
        • Masoudi F.A.
        • Nallamothu B.K.
        ACC/AHA 2008 performance measures for adults with ST-elevation and non–ST-elevation myocardial infarction: a report of the ACC/AHA Task Force on Performance Measures.
        J Am Coll Cardiol. 2008; 52: 2046-2099
        • Chen Z.M.
        • Pan H.C.
        • Chen Y.P.
        • Peto R.
        • Collins R.
        • Jiang L.X.
        • Xie J.X.
        • Liu L.S.
        Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
        Lancet. 2005; 366: 1622-1632
        • Setoguchi S.
        • Glynn R.J.
        • Avorn J.
        • Levin R.
        • Winkelmayer W.C.
        Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons > or = 65 years of age.
        Am J Cardiol. 2007; 100: 1061-1067
        • Vega D.D.
        • Dolan K.L.
        • Pollack M.L.
        Beta-blocker use in elderly ED patients with acute myocardial infarction.
        Am J Emerg Med. 2006; 24: 435-439
        • Alexander K.P.
        • Newby L.K.
        • Armstrong P.W.
        • Cannon C.P.
        • Gibler W.B.
        • Rich M.W.
        • Van de Werf F.
        • White H.D.
        • Weaver W.D.
        • Naylor M.D.
        • Gore J.M.
        • Krumholz H.M.
        • Ohman E.M.
        Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the AHA Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
        Circulation. 2007; 115: 2570-2589
        • Skolnick A.H.
        • Alexander K.P.
        • Chen A.Y.
        • Roe M.T.
        • Pollack Jr, C.V.
        • Ohman E.M.
        • Rumsfeld J.S.
        • Gibler W.B.
        • Peterson E.D.
        • Cohen D.J.
        Characteristics, management, and outcomes of 5,557 patients age > or = 90 years with acute coronary syndromes: results from the CRUSADE initiative.
        J Am Coll Cardiol. 2007; 49: 1790-1797